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Abstract
Background: Mannitol has been used in the past for the prevention of cisplatin-induced nephrotoxicity. Studies on its efficacy
have conflicting results. An educational newsletter was designed for local oncologists on the conflicting data of mannitol use
in preventing cisplatin-induced nephrotoxicity. Purpose: The purpose of this study was to determine whether a pharmacistcreated newsletter intervention led to changes in the mannitol prescribing practices of local oncologists. Methods: A newsletter
describing the paucity of evidence to support mannitol use to prevent cisplatin-induced nephrotoxicity was distributed via e-mail
to local oncologists in October 2010. Mannitol prescribing rates were retrospectively evaluated before and after newsletter
distribution. The Mann-Whitney U test was used to compare nonparametric continuous data. The chi-square test was used for
nominal data. Descriptive statistics were performed for baseline demographics, and odds ratios were calculated for possible risk
factors for acute kidney injury (AKI). The primary endpoint was a change in mean mannitol dose before and after the newsletter
intervention. The secondary endpoint was the difference in the rate of AKI before and after the intervention. Data were
collected for 67 patients with various malignancies. Results: There was a difference in the average mannitol dose before and
after newsletter intervention (P = .02). The rates of AKI before and after newsletter were similar. Conclusion: A pharmacistled newsletter intervention was associated with significantly decreased rates of mannitol usage after intervention.
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Cisplatin was the first platinum agent discovered to have
oncological activities, and it is used in the treatment of many
malignancies including testicular, head and neck, lung, gynecologic, and other cancers. Cisplatin causes significant toxicities such as nausea, vomiting, ototoxicity, electrolyte
abnormalities, and nephrotoxicity. Nephrotoxicity was cisplatin’s major dose-limiting adverse effect until pretreatment
and posttreatment hydration became a standard preventive
measure.1 Despite this, nephrotoxicity may still occur, leading to dose delays and treatment cessation. Cisplatin’s package insert states that 28% to 36% of patients treated with a
single dose of cisplatin (50 mg/m2) can experience nephrotoxicity, which is manifested as elevations in blood urea
nitrogen and serum creatinine (SCr).2 In addition to hydration, forced diuresis with mannitol has been used to minimize cisplatin-induced nephrotoxicity.
Mannitol is an osmotic diuretic that is indicated for the
promotion of diuresis; it is a logical choice for reduction of
cisplatin-induced nephrotoxicity as it is nontoxic and could
reduce the half-life of cisplatin in the kidney.3 However,
studies have not demonstrated a clearly consistent
benefit of mannitol use in preventing cisplatin-induced

nephrotoxicity.4-6 Readers are referred to a thorough review
of this topic for more in-depth information, which concluded, “There are no compelling data that the addition of
mannitol is more nephroprotective than the use of hydration alone.”7 In reflection of this, an educational newsletter
was prepared and e-mailed to oncologists on the lack of
data to support mannitol’s use for preventing cisplatininduced nephrotoxicity with the hope of decreasing mannitol prescribing. The objective of this study was to
determine whether a pharmacist-created newsletter intervention led to changes in the mannitol prescribing practices
of local oncologists.
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Methods

Statistical Analysis

Study Design

The Mann-Whitney U test was used to compare nonparametric continuous data. The chi-square test was used for nominal
data. Descriptive statistics were performed for baseline demographics, and a univariate analysis was performed with odds
ratios calculated for possible risk factors for cisplatin-induced
nephrotoxicity (cisplatin dose, mannitol use, hypertension,
diabetes, female gender, feeding tube, radiation therapy, and
concomitant nephrotoxin use). All statistical analyses were
calculated using PASW Statistics 18 (SPSS, Chicago, Illinois).
The primary endpoint was the change in mean mannitol
dose prescribed before and after the newsletter intervention.
Secondary endpoints included rate of AKI before and after
the newsletter intervention and possible risk factors for AKI.

Educational newsletters were developed monthly by
Advanced Pharmacy Practice Experience (APPE) students. Topics were selected by the APPE preceptor (J.B.B.)
who edited the newsletter after the revision process.
Topics focused on supportive care of oncology patients
and techniques to minimize toxicity from chemotherapy.
To encourage readability, the newsletters were short (1-2
pages) and included figures or tables to easily communicate information. In October 2010, an educational newsletter (eAppendix) was delivered electronically to all
institutional oncologists, oncology nurses, and oncology
pharmacists that described the state of evidence at that
time for using mannitol to prevent cisplatin-induced
nephrotoxicity.
To determine whether the newsletter changed prescribing
practices, a retrospective chart review of patients treated for
the first time with cisplatin at Johnson City Medical Center
(JCMC) and the Regional Cancer Center (RCC) was conducted. Patients were identified by pharmacy billing records
for cisplatin followed by a review of electronic medical
records. This study was approved by East Tennessee State
University Institutional Review Board.

Results
A total of 85 patients were identified via the pharmacy database; 18 were excluded, leaving a total of 67 patients for statistical analysis. Reasons for exclusion included being
previously treated with cisplatin (14 patients), incomplete
medical records for assessment (1 patient), and age younger
than 18 years (3 patients). Thirty patients were included in
the prenewsletter cohort, and 37 patients were included in
the postnewsletter cohort.

Study Population and Data Collection

Demographics

JCMC is a 445-bed community hospital and a member of
the Mountain States Health Alliance (MSHA). The MSHA
RCC includes a 21-bed outpatient infusion suite and physician clinics. Patients receiving their first dose of cisplatin at
JCMC or RCC during the study period were included. The
study period included prenewsletter (January 1, 2010, to
June 30, 2010) and postnewsletter (January 1, 2011, to
December 31, 2011) cohorts around the time of newsletter
publication (October 2010) with a 6-month gap to allow for
diffusion of information. Patients younger than 18 years,
those who initiated cisplatin treatment outside the study
periods, and those with incomplete medical records were
excluded.
Information regarding each patient’s cancer diagnosis and
stage, nephroprotective strategy for cisplatin (including
mannitol use and dose), demographics, diabetes or hypertension history, treatment regimen (monotherapy or in combination with either chemotherapy or radiation therapy), the use
of concomitant nephrotoxins, prescriber, use of feeding tube,
cisplatin dose and number of doses, baseline SCr and creatinine clearance (CrCl) (including peak SCr and CrCl), and
acute kidney injury (AKI) incidence, grade, and time to AKI
were recorded. In the case of AKI, a grade of 0 to 5 was
assigned based upon the Common Terminology Criteria for
Adverse Events version 4.0.8

The patients’ demographic data for both the prenewsletter
and postnewsletter cohorts are summarized in Table 1.
Patients were almost entirely Caucasian, and there was an
approximately equal gender distribution. The median age of
the prenewsletter cohort was 59 years (range, 33-74 years),
and the median age of the postnewsletter cohort was 57 years
(range, 40-76 years). Patient characteristics were similar
between the prenewsletter and postnewsletter cohorts with
the exception of primary tumor sites. In the prenewsletter
cohort, more patients had lung cancer or other as the primary
tumor site, whereas in the postnewsletter cohort, more
patients had head/neck as the primary tumor site. Most
patients in the prenewsletter cohort were receiving radiation
(66.67%) and other chemotherapy (76.67%). The majority of
patients in the postnewsletter cohort were also receiving
radiation (81.08%) and other chemotherapy (83.78%).
Patients in both cohorts were likely to be on concomitant
nephrotoxins: 83.3% in the prenewsletter cohort and 97.3%
in the postnewsletter cohort. Mean baseline renal function
was normal in both cohorts.
The average dose of mannitol (Table 2) in the prenewsletter cohort was 12.75 g, with the average dose of mannitol in
the postnewsletter cohort decreasing to 4.14 g (P = .02). The
average cisplatin dose in the prenewsletter group was 59.4
mg versus 54.9 mg in the postnewsletter group (P = .34).
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Table 1. Patient Characteristics (N = 67).
Characteristic
Age, y
Median
Range
Sex
Male
Race, n (%)
Caucasian
African American
Other
Primary tumor site, n (%)
Head/neck
Lung
Other
Stage, n (%)
Locally advanced
Metastatic
Comorbidities, n (%)
Diabetes
Hypertension
Feeding tube, n (%)
Yes
Radiation, n (%)
Yes
Chemotherapy, n (%)
Combination
Concomitant nephrotoxin
NSAID
ACE/ARB
Diuretic
Other (eg, IV contrast)
Baseline renal function
SCr, mg/dL
CrCl, mL/min

Table 3. Univariate Analysis of Acute Kidney Injury.

Prenewsletter
cohort (n = 30)

Postnewsletter
cohort (n = 37)

59
33-74

57
40-76

15 (50)

20 (54.1)

28 (93.3)
1 (3.3)
1 (3.3)

35 (94.6)
0 (0)
2 (5.4)

6 (20)
17 (56.7)
7 (23.3)

32 (86.5)
5 (13.5)
0 (0)

16 (53.3)
14 (46.7)

18 (48.6)
19 (51.4)

6 (20)
16 (53.33)

5 (13.51)
21 (56.76)

4 (13.33)

8 (21.62)

20 (66.67)

30 (81.08)

23 (76.67)
25 (83.3)
8 (26.7)
12 (40)
8 (26.7)
18 (60)

31 (83.78)
36 (97.3)
8 (21.6)
11 (29.8)
9 (24.3)
35 (94.6)

0.81
109.9

0.76
112.5

Note. NSAID = nonsteroidal anti-inflammatory drug; ACE = angiotensinconverting enzyme inhibitor; ARB = angiotensin receptor blocker;
SCr = serum creatinine; CrCl = creatinine clearance; IV = intravenous.

Table 2. Results Before and After Newsletter
Implementation.

Cisplatin dose, average
Mannitol dose, average
Rate of AKI
AKI grade, median

Before
newsletter
(n = 30)

After
newsletter
(n = 37)

P value

59.4 mg
12.75 g
40%
1

54.9 mg
4.14 g
43%
1

.34a
.02a
.79b
.985c

Note. AKI = acute kidney injury.
a
Mann-Whitney U test.
b
Chi-square test.
c
Independent-samples median test.

Feeding tube
Radiation therapy
Hypertension
Cisplatin dose >75 mg/m2
Nephrotoxin
Mannitol use
Diabetes mellitus
Female gender

Odds ratio

95% CI

2.27
2.04
1.89
1.55
1.49
1.46
1.19
0.71

0.67-8.07
0.63-6.67
0.70-5.13
0.58-4.16
0.25-8.74
0.53-4.03
0.326-4.39
0.57-1.89

Note. CI = confidence interval.

Of the 67 patients, 12 (40%) in the prenewsletter group
experienced any grade AKI, whereas 16 (43%) in the postnewsletter group experienced any grade AKI (P = .79; Table
2). No risk factors were identified for AKI (Table 3).

Discussion
A newsletter as part of a comprehensive pharmacist-led
education program has been shown to influence prescribing
behavior.9 Our 2-page newsletter appeared to change prescriber behavior as well but, as with any retrospective
study, uncontrolled confounders may exist. One factor that
may have affected mannitol prescribing was education
regarding cisplatin nephroprotection strategies on inpatient
rounds. After the newsletter was distributed, the clinical
pharmacist on the inpatient rounding service began reviewing the data presented in the newsletter on a patient-specific
basis when cisplatin was prescribed. The influence of this
face-to-face education on the results was likely mitigated
by allowing a 6-month gap between cohorts for diffusion of
information.
Given that higher doses (>75 mg/m2) of cisplatin were not
associated with nephrotoxicity, the study population may
have been underpowered due to its small sample size (N =
67). In addition, there may be confounding differences in
baseline demographics. The prenewsletter group consisted
primarily of lung cancer patients (56.7%), whereas the postnewsletter group consisted primarily of head and neck cancer
patients (86.5%). As different chemotherapy regimens are
used for different malignancies, this could have affected the
results. However, the similar mean cisplatin dose in both
cohorts argues against this. Our study also suffers from the
inherent limitations of retrospective studies.
Mannitol’s role as a nephroprotective agent remains unclear.
Morgan et al10 published data from a quasi-experiment recently
that differed from previous studies; they presented evidence
that mannitol does decrease cisplatin-induced nephrotoxicity.
There were methodological differences between the study by
Morgan et al and our study, including stricter inclusion criteria
as patients could only have received cisplatin monotherapy for
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any nongynecological solid tumor. The study also had a larger
patient population (N = 143) than our study, with 3 different
cisplatin dosing groups assessed. Another key difference was a
standard mannitol regimen in which all doses were the same
compared with community-based dosing dependent on physician preference. Unfortunately, our study focused primarily on
mannitol prescribing practices and therefore could not control
the many confounders affecting cisplatin-induced AKI.
Despite several retrospective studies and limited randomized studies, the effect of mannitol on preventing cisplatininduced nephrotoxicity remains unclear. Given cisplatin’s
widespread utility in the oncology world, reliable evidencebased guidelines for preventing cisplatin-induced nephrotoxicity are needed. Prospective research should be considered a
top priority to better address this concern.

Conclusion
A pharmacist-led newsletter intervention to educate prescribers appeared to change prescribing practices of mannitol. No
risk factors were identified, including mannitol use, for cisplatin-induced nephrotoxicity. Randomized trials are needed
to truly assess any benefit from mannitol use in patients
receiving cisplatin.
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